Journal of the American Academy of Dermatology

Rapid and sustained improvements in GPPGA scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. 2023

The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis.  88:169-172. 2023

Development of a core outcome set for basal cell carcinoma.  87:573-581. 2022

Cost efficacy of wide local excision of pT1a melanoma in office versus operating room settings.  86:1174-1176. 2022

Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria 2022

An increase in respiratory protection device injuries associated with the COVID-19 pandemic.  85:973-975. 2021

Dietary table grape protects against ultraviolet photodamage in humans: 1. clinical evaluation.  85:1030-1032. 2021

Dietary table grape protects against ultraviolet photodamage in humans: 2. molecular biomarker studies.  85:1032-1034. 2021

Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study.  84:1140-1142. 2021

Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.  84:1113-1119. 2021

Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.  84:432-470. 2021

Improvement of 11 patients with nail psoriasis with apremilast: Results of an investigator-initiated open-label study.  83:1830-1832. 2020

Efficacy of staged excision with permanent section margin control for melanoma in situ.  83:1163-1164. 2020

No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.  83:375-381. 2020

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.  82:1445-1486. 2020

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.  82:161-201. 2020

Negative predictive value of biopsy margins of dysplastic nevi: A single-institution retrospective review.  82:87-93. 2020

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.  81:775-804. 2019

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.  80:1073-1113. 2019

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.  80:1029-1072. 2019

More than keratitis, ichthyosis, and deafness: Multisystem effects of lethal GJB2 mutations.  80:617-625. 2019

Association of 25-hydroxyvitamin D levels and cutaneous melanoma: A nested case-control study of the Women's Health Initiative Observation Study.  79:145-147. 2018

Guidelines of care for the management of basal cell carcinoma.  78:540-559. 2018

Guidelines of care for the management of cutaneous squamous cell carcinoma.  78:560-578. 2018

Validity of skin cancer malignancy reporting to the Organ Procurement Transplant Network: A cohort study.  78:264-269. 2018

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.  78:90-99.e1. 2018

Randomized controlled pilot study of the preoperative use of brimonidine 0.33% topical gel for hemostasis in Mohs micrographic surgery.  77:1114-1118. 2017

High prevalence of combination tanning among undergraduates: Survey at a southeastern US university.  77:968-970. 2017

Histopathologic features of melanoma in difficult-to-diagnose lesions: A case-control study.  77:543-548.e1. 2017

Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.  77:79-87.e1. 2017

The impact of oral Polypodium leucotomos extract on ultraviolet B response: A human clinical study.  77:33-41.e1. 2017

Predicting neurofibromatosis type 1 risk among children with isolated café-au-lait macules.  76:1077-1083.e3. 2017

Response to A financial perspective on the topical treatment of onychomycosis.  75:e39. 2016

Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.  73:62-69. 2015

Successful treatment of refractory Hailey-Hailey disease with a 595-nm pulsed dye laser: A series of 7 cases.  72:735-737. 2015

Tanning accelerators: Prevalence, predictors of use, and adverse effects.  72:99-104. 2015

Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches Work Group.  71:1218-1233. 2014

Using better understanding of anatomy to improve surgical assistants' utility.  71:e245-e246. 2014

Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site..  70:1002-1009. 2014

Erratum: Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies(Journal of the American Academy of Dermatology (2013) 68 (600-8)).  70:399. 2014

Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis Work Group.  70:338-351. 2014

Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies.  71:116-132. 2014

Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents.  71:327-349. 2014

Research gaps in psoriasis: Opportunities for future studies.  70:146-167. 2014

Rickettsia parkeri: Eschar diagnosis.  71. 2014

Sirolimus-associated regression of benign lymphangioendothelioma.  71:e221-e222. 2014

Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser.  69:578-582. 2013

Elastic staining versus fluorescent and polarized microscopy in the diagnosis of alopecia.  69:288-293. 2013

Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.  68:600-608. 2013

Ulcerative lesions in an advanced AIDS patient.  68. 2013

Skin cancer risk perceptions: A comparison across ethnicity, age, education, gender, and income.  66:771-779. 2012

Compliance with sunscreen advice in a survey of adults engaged in outdoor winter recreation at high-elevation ski areas.  66:63-70. 2012

Lichen planus pemphigoides in a 2-year-old girl: Response to treatment with methotrexate.  67. 2012

Neutrophilic dermatosis revisited: An initial presentation of lupus?.  67. 2012

Dermatomyositis and concomitant overlap myasthenic syndrome: A rare presentation.  65. 2011

Fulminant myocarditis as a late sequela of DRESS: Two cases.  65:889-890. 2011

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions.  65:137-174. 2011

Phenotypic variability among café-au-lait macules in neurofibromatosis type 1.  63:440-447. 2010

Cyclosporine and psoriasis: 2008 National Psoriasis Foundation^* Consensus Conference.  62:838-853. 2010

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.  62:114-135. 2010

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.  61:451-485. 2009

Neurofibromatosis type 1.  61:1-14. 2009

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.  60:643-659. 2009

Lack of classic histology should not prevent diagnosis of necrolytic acral erythema.  60:504-507. 2009

Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: Results of two randomized, investigator-blinded, multicenter, international, controlled trials^*.  59:41-54. 2008

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.  58:826-850. 2008

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics.  58:851-864. 2008

The prevalence of acne in adults 20 years and older.  58:56-59. 2008

Reply.  57:728. 2007

Onychomycosis: Diagnosis and definition of cure.  56:939-944. 2007

New opportunities in preventative dermatology: How far should we go?.  56:675-676. 2007

Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.  56:439.e1-439.e10. 2007

Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.  54. 2006

A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis.  53:798-809. 2005

Surgical Pearl: Preventing perioperative exposure keratopathy.  53:707-708. 2005

Surgical Pearl: The "fishhook" needle technique: A solution to the large needle, small space dilemma.  53:144-146. 2005

Cutaneous lymphoid hyperplasia and marginal zone B-cell lymphoma following vaccination.  53:511-515. 2005

Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma.  52:798-802. 2005

Modification of the nail psoriasis severity index [8] (multiple letters).  53:745-746. 2005

Molecular diagnostics in melanoma.  52:743-775. 2005

Randomized, controlled surgical trial of preoperative tumor curettage of basal cell carcinoma in Mohs micrographic surgery.  51:585-591. 2004

Improvement in nail psoriasis with alefacept.  50:p145. 2004

Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002.  50:748-752. 2004

Guidelines of care for atopic dermatitis.  50:391-404. 2004

Tinea capitis in adult women masquerading as bacterial pyoderma.  49:177-179. 2003

Tinea capitis in adult women masquerading as bacterial pyoderma..  49:S177-S179. 2003

Tinea capitis in Cleveland: Survey of elementary school students.  48:189-193. 2003

Cutaneous anthrax management algorithm.  47:766-769. 2002

Infliximab for the treatment of severe pustular psoriasis [1].  47:796-797. 2002

Reactivity to trichophytin antigen in patients with onychomycosis: Effect of terbinafine.  46:371-375. 2002

Reply.  45:320-321. 2001

A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma.  44:940-947. 2001

Cutaneous photoprotection from ultraviolet injury by green tea polyphenols.  44:425-432. 2001

Facial and abdominal hair growth in hirsutism: A computerized evaluation.  45:846-850. 2001

Guidelines of care for liposuction.  45:438-447. 2001

Ovarian hormones and adrenal androgens during a woman’s life span.  45:S105-S115. 2001

Surgical pearl: Hemostat-assisted nail avulsion revisited.  45:943-944. 2001

Tinea capitis of childhood: Incidence and pathogenetic role, of Trichophyton tonsurans in Central Europe [4] (multiple letters) [4].  45:320-321. 2001

A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns.  43:641-648. 2000

Erratum: Tinea capitis: A current perspective (Journal of the American Academy of Dermatology (January 2000) 42 (1-20)).  42:704. 2000

Tinea capitis: A current perspective.  42:1-20. 2000

Tinea capitis: A current perspective.  42:1-20. 2000

Tinea capitis: a current perspective..  42:1-20. 2000

Merkel cell carcinoma occurring in renal transplant patients..  41:289-291. 1999

Merkel cell carcinoma occurring in renal transplant patients.  41:289-291. 1999

Novel treatment strategies for superficial mycoses: Introduction.  40. 1999

Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method.  40:S9. 1999

Treatment of tinea capitis: Beyond griseofulvin.  40. 1999

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail..  38:S87-S94. 1998

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail..  38:S77-S86. 1998

Once-weekly fluconazole in the treatment of onychomycosis: introduction..  38:S73-S76. 1998

Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail..  38:S103-S109. 1998

Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail..  38:S110-S116. 1998

Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.  39:63-73. 1998

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail.  38. 1998

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.  38. 1998

Once-weekly fluconazole in the treatment of onychomycosis: Introduction.  38. 1998

Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail.  38. 1998

Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail.  38. 1998

Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial..  37:740-745. 1997

A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the tingemail.  36:231-235. 1997

Bacterial infection in a patient with onychomycosis.  37:493-494. 1997

One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: A multicenter, double-blind trial.  36. 1997

Onychomycosis in children: Prevalence and treatment strategies.  36:395-402. 1997

Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial.  37:740-745. 1997

Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream.  36. 1997

Diagnostic techniques for confirming onychomycosis..  35:S6-S9. 1996

Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study..  35:216-219. 1996

Reply.  35:135. 1996

Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology..  34:287-289. 1996

Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. Guidelines/Outcomes Committee. American Academy of Dermatology..  34:290-294. 1996

Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology..  34:282-286. 1996

Surgical pearl: nail micronizer..  34:278. 1996

A U.S. epidemiologic survey of superficial fungal diseases.  35:539-542. 1996

Clinical pearl: Diagnostic procedures for tinea capitis.  34:498-499. 1996

Diagnostic techniques for confirming onychomycosis.  35. 1996

Guidelines of care for superficial mycotic infections of the skin: Mucocutaneous candidiasis.  34:110-115. 1996

Guidelines of care for superficial mycotic infections of the skin: Onychomycosis.  34:116-121. 1996

Guidelines of care for superficial mycotic infections of the skin: Piedra.  34:122-124. 1996

Intermittent fluconazole dosing in patients with onychomycosis: Results of a pilot study.  35:216-219. 1996

Onychomycosis caused by Scytalidium dimidiatum.  35:336-338. 1996

Surgical pearl: Nail micronizer.  34:278. 1996

Systemic antifungal drugs and drug interactions [2].  35:134-135. 1996

Thrombocytopenia caused by fluconazole [4].  35:284. 1996

Antifungal agents.  32:1060. 1995

Bonsai tree: Risk factor for disseminated sporotrichosis.  33:839-840. 1995

Clinical Pearl: Systemic antifungal drugs and drug interactions.  33:259-260. 1995

Clinical pearl: Diagnosis of onychomycosis.  32:500-501. 1995

Cost of therapy for dermatophyte infections.  32:1062. 1995

Cutaneous involvement with Cryptococcus neoformans in AIDS [4].  32:820-821. 1995

Cutaneous photosensitivity diseases induced by exogenous agents.  33:551-573. 1995

Failure of clotrimazole-betamethasone dipropionate cream in treatment of Microsporum canis infections.  32:1050-1051. 1995

Long-term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole.  32:290-292. 1995

Reply.  32:821. 1995

Thrombocytopenia caused by fluconazole therapy.  32:525-526. 1995

Zosteriform zygomycosis.  32:357-361. 1995

Management of common superficial fungal infections in patients with AIDS..  31:S60-S63. 1994

Cutaneous involvement with Cryptococcus neoformans in AIDS.  30:844-848. 1994

Dermatophytes as opportunistic pathogens.  30:1021-1022. 1994

Introduction: International Summit on Cutaneous Antifungal Therapy.  31:S1. 1994

Management of common superficial fungal infections in patients with AIDS.  31:S60-S63. 1994

Tinea capitis: Itraconazole in Trichophyton tonsurans infection.  31:65-67. 1994

Malignant fibrous histiocytoma resembling mycetoma..  29:318-321. 1993

Mechanisms of action of systemic antifungal agents..  28:S28-S34. 1993

Clinical Pearl: Proximal white subungual onychomycosis in AIDS.  29:631-632. 1993

Malignant fibrous histiocytoma resembling mycetoma.  29:318-321. 1993

Mechanisms of action of systemic antifungal agents.  28:S28-S34. 1993

Childhood epidermolysis bullosa acquisita. Report of three cases and review of literature..  24:706-714. 1991

Eosinophilic pustular folliculitis..  24:903-907. 1991

Childhood epidermolysis bullosa acquisita: Report of three cases and review of literature.  24:706-714. 1991

Eosinophilie pustular folliculitis.  24:903-907. 1991

Pigmented postacne osteoma cutis in a patient treated with minocycline: Report and review of the literature.  24:851-853. 1991

Leukocytoclastic vasculitis in a patient infected with human immunodeficiency virus..  21:1161-1164. 1989

The superficial mycoses and the dermatophytes..  21:655-673. 1989

Effects of occlusive and semiocclusive dressings on the return of barrier function to transepidermal water loss in standardized human wounds..  20:755-760. 1989

Effects of occlusive and semiocclusive dressings on the return of barrier function to transepidermal water loss in standardized human wounds.  20:755-760. 1989

Leukocytoclastic vasculitis in a patient infected with human immunodeficiency virus.  21:1161-1164. 1989

The superficial mycoses and the dermatophytes.  21:655-673. 1989

Antiviral treatment of a serious herpes simplex infection: Encephalitis.  18:209-211. 1988

Antiviral treatment of a serious herpes simplex infection: encephalitis..  18:209-211. 1988

Questions and answers.  18:207-208. 1988

Questions and answers.  18:222-223. 1988

Xanthogranulomatosis in an adult: Lipid analysis of xanthomas and plasma.  16:183-187. 1987

Xanthogranulomatosis in an adult: lipid analysis of xanthomas and plasma..  16:183-187. 1987

In vivo suppression of neutrophil chemotaxis by systemically and topically administered tetracycline.  8:807-812. 1983